RESUMO
OBJECTIVE: To assess the rate and type of genetic diagnosis and clinical outcome of cases of fetal cardiomyopathy (CM) during two eras, in order to examine the impact of advanced genetic testing and improved perinatal management strategies. METHODS: All diagnoses of fetal CM in Alberta, Canada, encountered between 2003 and 2019, were reviewed retrospectively. Genetic, cardiac and non-cardiac diagnoses and clinical outcome were documented. Cases with CM secondary to extracardiac pathology and maternal conditions were excluded. Cases diagnosed in the earlier era of the study period (2003-2012) were compared with those diagnosed in the later era (2013-2019). RESULTS: Thirty-eight cases of fetal CM met the inclusion criteria. Median gestational age (GA) at diagnosis was 22.8 (range, 13.4-37.4) weeks. Associated structural heart disease was present in 39% (15/38) of cases and 24% (9/38) had arrhythmia. Hydrops was identified in 29% (11/38) of cases at presentation, and a further 18% (7/38) developed hydrops later in gestation. Twenty-six percent (10/38) of cases underwent termination of pregnancy and 24% (9/38) had intrauterine death. Of liveborn cases, neonatal death occurred in 16% (3/19), late death occurred in 21% (4/19) and 63% (12/19) were alive at the last follow-up. Excluding cases that had termination of pregnancy and those with a liveborn infant who received planned palliative care, the rate of neonatal survival was higher in the later compared with the earlier era (69% (11/16) vs 45% (5/11)), although the difference was not statistically significant (P = 0.26). A genetic etiology was confirmed in 39% (15/38) of cases and strongly suspected in 24% (9/38). A significantly higher proportion of cases had a confirmed or strongly suspected genetic etiology in the later era compared with in the earlier era (76% (19/25) vs 38% (5/13); P = 0.04). CONCLUSIONS: In the recent era, a higher proportion of fetal CM cases had a confirmed or strongly suspected genetic etiology than reported previously. Based on comparison with older series, modern perinatal management strategies may not have a significant impact on neonatal survival in cases of fetal CM; however, a larger study would be better powered to detect more subtle differences. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
Assuntos
Cardiomiopatias , Resultado da Gravidez , Cardiomiopatias/genética , Edema , Feminino , Idade Gestacional , Humanos , Lactente , Recém-Nascido , Gravidez , Estudos Retrospectivos , Ultrassonografia Pré-NatalRESUMO
BACKGROUND: Freedom from rejection in pediatric heart transplant recipients is highly variable across centers. This study aimed to assess the center variation in methods used to diagnose rejection in the first-year post-transplant and determine the impact of this variation on patient outcomes. METHODS: The PHTS registry was queried for all rejection episodes in the first-year post-transplant (2010-2019). The primary method for rejection diagnosis was determined for each event as surveillance biopsy, echo diagnosis, or clinical. The percentage of first-year rejection events diagnosed by surveillance biopsy was used to approximate the surveillance strategy across centers. Methods of rejection diagnosis were described and patient outcomes were assessed based on surveillance biopsy utilization among centers. RESULTS: A total of 3985 patients from 56 centers were included. Of this group, 873 (22%) developed rejection within the first-year post-transplant. Surveillance biopsy was the most common method of rejection diagnosis (71.7%), but practices were highly variable across centers. The majority (73.6%) of first rejection events occurred within 3-months of transplantation. Diagnosis modality in the first-year was not independently associated with freedom from rejection, freedom from rejection with hemodynamic compromise, or overall graft survival. CONCLUSIONS: Rejection in the first-year after pediatric heart transplant occurs in 22% of patients and most commonly in the first 3 months post-transplant. Significant variation exists across centers in the methods used to diagnose rejection in pediatric heart transplant recipients, however, these variable strategies are not independently associated with freedom from rejection, rejection with hemodynamic compromise, or overall graft survival.
Assuntos
Rejeição de Enxerto/diagnóstico , Transplante de Coração/efeitos adversos , Padrões de Prática Médica , Adolescente , Fatores Etários , Criança , Feminino , Rejeição de Enxerto/etiologia , Humanos , Masculino , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Fatores de TempoRESUMO
The immunogenicity of standard intramuscular (IM) influenza vaccine is suboptimal in transplant recipients. Also, recent studies suggest that alloantibody may be upregulated due to vaccination. We evaluated a novel high-dose intradermal (ID) vaccine strategy. In conjunction, we assessed alloimmunity. Transplant recipients were randomized to receive IM or high-dose ID vaccine. Strain-specific serology and HLA alloantibody production was determined pre- and postimmunization. In 212 evaluable patients (105 IM, 107 ID), seroprotection to H1N1, H3N2 and B strains was 70.5%, 63.8% and 52.4% in the IM group, and 71.0%, 70.1%, 63.6% in the ID group (p=ns). Seroconversion to ≥1 antigen was 46.7% and 51.4% in the IM and ID groups respectively (p=0.49). Response was more likely in those≥6 months posttransplant (53.2% vs. 19.2%; p=0.001). Use of mycophenolate mofetil was inversely associated with vaccine response in a dose-dependent manner (p<0.001). Certain organ subgroups had higher response rates for influenza B in the ID vaccine group. Differences in anti-HLA antibody production were detected in only 3/212(1.4%) patients with no clinical consequences. High-dose intradermal vaccine is an alternative to standard vaccine and has potential enhanced immunogenicity in certain subgroups. In this large cohort, we also show that seasonal influenza does not result in significant alloantibody production.
Assuntos
Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/efeitos adversos , Injeções Intradérmicas/efeitos adversos , Injeções Intramusculares/efeitos adversos , Transplante de Órgãos , Adulto , Idoso , Relação Dose-Resposta a Droga , Feminino , Humanos , Terapia de Imunossupressão/efeitos adversos , Vírus da Influenza A Subtipo H1N1 , Vírus da Influenza A Subtipo H3N2 , Vírus da Influenza B , Influenza Humana/prevenção & controle , Isoanticorpos/imunologia , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Estudos Prospectivos , Resultado do Tratamento , Adulto JovemRESUMO
Specific B-cell tolerance toward donor blood group antigens develops in infants after ABO-incompatible heart transplantation, whereas their immune response toward protein antigens such as HLA has not been investigated. We assessed de novo HLA-antibodies in 122 patients after pediatric thoracic transplantation (28 ABO-incompatible) and 36 controls. Median age at transplantation was 1.7 years (1 day to 17.8 year) and samples were collected at median 3.48 years after transplantation. Antibodies were detected against HLA-class I in 21 patients (17.2%), class II in 18 (14.8%) and against both classes in 10 (8.2%). Using single-antigen beads, donor-specific antibodies (DSAs) were identified in six patients (all class II, one additional class I). Patients with DSAs were significantly older at time of transplantation. In patients who had undergone pretransplant cardiac surgeries, class II antibodies were more frequent, although use of homografts or mechanical heart support had no influence. DSAs were absent in ABO-incompatible recipients and class II antibodies were significantly less frequent than in children with ABO-compatible transplants. This difference was present also when comparing only children transplanted below 2 years of age. Therefore, tolerance toward the donor blood group appears to be associated with an altered response to HLA beyond age-related effects.
Assuntos
Antígenos HLA/imunologia , Transplante de Coração/imunologia , Isoanticorpos/sangue , Sistema ABO de Grupos Sanguíneos , Adolescente , Fatores Etários , Tipagem e Reações Cruzadas Sanguíneas , Estudos de Casos e Controles , Criança , Pré-Escolar , Feminino , Sobrevivência de Enxerto/imunologia , Antígenos HLA-D/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Teste de Histocompatibilidade , Humanos , Lactente , Recém-Nascido , Masculino , Fatores de Risco , Doadores de TecidosRESUMO
In the first two yr of life blood-group incompatible (ABO-incompatible) heart transplantation can be performed leading to immune tolerance to donor blood group. Antibody titers should be below 1:4. VAD use is correlated with sensitization toward blood-group antigens. A boy was diagnosed with dilated cardiomyopathy at nine months of age and listed for 0-compatible transplantation. Progressive heart failure required implantation of a left VAD. His listing was extended for ABO-incompatible transplantation despite antibody titers of 1:32 anti-A and 1:8 anti-B. After 26 days on VAD, he was transplanted with a B donor heart. No hyperacute or acute rejection occurred in 12 months post-transplant. Anti-B antibodies rose to a maximum of 1:2. No use of rituximab or plasmapheresis was required. There are no signs of graft vasculopathy. This indicates that inclusion criteria for ABO-incompatible transplantation may be extended to immediate cases. This is the first case with a healthy immune system to show signs of tolerance development after ABO-incompatible heart transplantation with increased prior antibody titers and without specific treatment.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Transplante de Coração/métodos , Coração Auxiliar , Incompatibilidade de Grupos Sanguíneos/imunologia , Rejeição de Enxerto , Insuficiência Cardíaca/terapia , Humanos , Sistema Imunitário , Lactente , Masculino , Fatores de Tempo , Tolerância ao Transplante , Resultado do TratamentoRESUMO
UNLABELLED: Recurrent pericarditis is a rare disease in childhood. Nevertheless, it may represent a challenge to the clinician due to its resistance to anti-inflammatory treatment. The initial etiology often remains unclear; specific laboratory parameters predicting the frequency or severity of the recurrences are lacking. We report on four patients with recurrent pericarditis in whom antimyolemmal antibodies (AMLAs) were detected. A prolonged persistence of IgM-type AMLAs was found in three patients: two of them presented with acute inflammation as the initial event and one with 48 recurrences during 5.5 years. The fourth patient showed a fast conversion from IgM to IgG-type AMLAs after a less acute initial presentation and showed 4 mild recurrences during the 48-month follow-up. CONCLUSION: We were able to detect AMLAs in four children with recurrent pericarditis. This finding may be attributed to an auto-immunological disease following a first, acute event. We propose the detection of AMLAs in all children with unexplained recurrent pericarditis. Pediatric patients with a persistence of IgM-type AMLAs may face frequent recurrences and should be monitored therefore more closely. In addition, medical treatment may be changed in these patients with a slower tapering of the dosage of steroidal and non-steroidal antiinflammatory drugs.
Assuntos
Autoanticorpos/imunologia , Pericardite/imunologia , Doença Aguda , Adolescente , Anti-Inflamatórios não Esteroides/uso terapêutico , Criança , Quimioterapia Combinada , Ecocardiografia , Feminino , Glucocorticoides/uso terapêutico , Humanos , Imunoglobulina G/imunologia , Imunoglobulina M/imunologia , Masculino , Pericardite/diagnóstico , Pericardite/tratamento farmacológico , Prognóstico , Prevenção Secundária , Resultado do TratamentoRESUMO
Characterization of the expression pattern of connexins in neural tissue is a necessary prerequisite for understanding the functional relevance of the corresponding gap junction channels in brain. Here we describe the cell type-specific expression of connexin45 in the CNS and the spatiotemporal expression pattern from embryonic day 19.5 to adult brain using a recently described connexin45 LacZ-reporter mouse. The connexin45 gene is highly expressed during embryogenesis and up to 2 weeks after birth in nearly all brain regions. Afterward its expression is restricted to the thalamus, the CA3 region of hippocampus and the cerebellum. In adult mouse brain, the pattern of LacZ-staining in combination with the analysis of different neuronal and glial marker proteins strongly suggests that connexin45 is expressed in neurons, but presumably not in astrocytes or mature oligodendrocytes. Expression of the LacZ/connexin45 reporter gene in subsets of neurons, such as cerebral cortical, hippocampal and thalamic neurons as well as basket and stellate cells of cerebellum should be corroborated by functional investigations of connexin45 protein in electrical synapses. Based on its expression pattern during development, we suggest that the connexin45-containing gap junction channels have a rather ubiquitous role during brain development and may contribute to functional specification in certain subsets of neurons in the adult brain.
Assuntos
Envelhecimento/genética , Encéfalo/embriologia , Encéfalo/crescimento & desenvolvimento , Diferenciação Celular/genética , Conexinas/genética , Junções Comunicantes/genética , Neurônios/metabolismo , Envelhecimento/metabolismo , Animais , Animais Recém-Nascidos , Biomarcadores , Encéfalo/metabolismo , Comunicação Celular/genética , Cerebelo/embriologia , Cerebelo/crescimento & desenvolvimento , Cerebelo/metabolismo , Córtex Cerebral/embriologia , Córtex Cerebral/crescimento & desenvolvimento , Córtex Cerebral/metabolismo , Conexinas/metabolismo , Feminino , Feto , Junções Comunicantes/metabolismo , Regulação da Expressão Gênica no Desenvolvimento/genética , Genes Reporter/genética , Imuno-Histoquímica , Óperon Lac/genética , Camundongos , Camundongos Transgênicos , Neuroglia/citologia , Neuroglia/metabolismo , Gravidez , Células-Tronco/citologia , Células-Tronco/metabolismo , Transcrição Gênica/genéticaAssuntos
Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , Antifúngicos/administração & dosagem , Infecções por HIV/imunologia , Pneumonia por Pneumocystis/prevenção & controle , Fármacos Anti-HIV/uso terapêutico , Contagem de Linfócito CD4 , Criança , Pré-Escolar , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , MasculinoRESUMO
Galectin-3 is a member of the galectin family of beta-galactoside-specific animal lectins. Here we show that galectin-3 is constitutively expressed in 15 out of 16 glioma cell lines tested, but not by normal or reactive astrocytes, oligodendrocytes, glial O-2A progenitor cells and the oligodendrocyte precursor cell line Oli-neu. Galectin-3 is also expressed by one oligodendroglioma cell line, but not by primitive neuroectodermal tumor and 4 neuroblastoma cell lines tested so far. In all galectin-3 expressing cell lines, the lectin is predominantly, if not exclusively, localized intracellularly and carries an active carbohydrate recognition domain (shown for C6 rat glioma cells). Moreover, in contrast to primary astrocytes, glioma cells do not or only weakly adhere to substratum-bound galectin-3, probably reflecting an unusual glycosylation pattern. Our findings indicate that the expression of galectin-3 selectively correlates with glial cell transformation in the central nervous system and could thus serve as a marker for glial tumor cell lines and glial tumors.
Assuntos
Antígenos de Diferenciação/metabolismo , Lectinas/metabolismo , Neuroglia/metabolismo , Animais , Animais Recém-Nascidos , Astrócitos/metabolismo , Western Blotting , Adesão Celular , Células Cultivadas , Galectina 3 , Glioma , Humanos , Imuno-Histoquímica , Camundongos , Neuroglia/patologia , Oligodendroglia/metabolismo , Ratos , Células Tumorais CultivadasRESUMO
In the present study we have analyzed the expression of galectin-3, a beta-galactoside-specific soluble animal lectin, by microglial cells in vitro. In enriched microglial cell cultures derived from neonatal mouse brain after 2 to 3 weeks in vitro, almost all microglial cells expressed galectin-3 intracellularly and about 90% expressed the molecule on the cell surface. Western blot analyses of lysates from microglial cells using galectin-3-specific antibodies revealed a single band with an apparent molecular weight of 29 kD. The carbohydrate recognition domain of microglia-derived galectin-3 was functional as the molecule could be affinity purified on lactose-agarose. Upon an incubation with lactose-, but not with sucrose-containing buffers the amount of cell surface expressed galectin-3 was strongly reduced, suggesting that the molecule appears to be associated with the plasma membrane via its carbohydrate recognition domain. The total amount as well as the portion of cell surface expressed galectin-3 increased upon treatment with granulocyte-macrophage colony-stimulating factor. Our findings suggest that galectin-3 expression is subject to regulation by growth factors supposed to be involved in the cascade of microglial activation under pathological conditions.